CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) saw some unusual options trading on Friday. Traders acquired 9,248 call options on the company. This is an increase of approximately 78% compared to the typical daily volume of 5,203 call options. Hedge Funds Weigh In On CRISPR Therapeutics Institutional investors have recently added to or reduced […]
CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) had its price objective lowered by analysts at Morgan Stanley from $43.00 to $42.00 in a note issued to investors on Monday, Benzinga reports. The firm currently has an “underweight” rating on the stock. Morgan Stanley’s price objective would suggest a potential downside of 24.05% from the company’s […]
CRISPR Therapeutics (NASDAQ:CRSP – Free Report) had its price objective trimmed by Needham & Company LLC from $88.00 to $85.00 in a research note released on Tuesday morning, Benzinga reports. The brokerage currently has a buy rating on the stock. A number of other equities analysts have also recently issued reports on the stock. JMP […]
Shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) shot up 7.9% during trading on Tuesday following a stronger than expected earnings report. The stock traded as high as $56.55 and last traded at $55.63. 1,305,716 shares traded hands during mid-day trading, an increase of 8% from the average session volume of 1,205,762 shares. […]
CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) had its target price decreased by equities research analysts at Royal Bank of Canada from $55.00 to $50.00 in a note issued to investors on Tuesday, Benzinga reports. The brokerage presently has a “sector perform” rating on the stock. Royal Bank of Canada’s price objective would suggest a […]